COLLEGEVILLE, Pa., Aug. 20 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , announced today that four researchers in the Company’s Chemical and Screening Sciences group were honored with awards presented at the 234th American Chemical Society National Meeting & Exposition in Boston this week:
-- Andrew Fensome, Ph.D., Principal Research Scientist II, received the prestigious David W. Robertson Award for Excellence in Medicinal Chemistry, which recognizes the outstanding contributions of young scientists that shape this field. As a contributing investigator on numerous studies of nonsteroidal progesterone receptor modulators, Dr. Fensome’s work on the development of nonsteroidal oral contraceptive agents has resulted in seven drug candidates that have advanced into development. -- Edmund I. Graziani, Ph.D., Principal Research Scientist II, received the Young Industrial Investigators Award for significant achievement, contributions and innovation, and outstanding promise for future contributions to organic chemistry. The award is given to scientists with no more than 10 years of experience since graduate school or postdoctoral appointment. -- Biqi Wu, M.S., Senior Research Scientist I, and Kevin Curran, B.A., Senior Research Scientist I, will each receive a Technical Achievement in Organic Chemistry (TAOC) Award. This award represents significant achievement and contributions to organic chemistry and is given to highly productive and creative BS/MS chemists.
“The recognition of these four scientists reflects the high quality of work being done throughout Wyeth Research, particularly in our chemistry group,” says Magid Abou-Gharbia, Ph.D., Senior Vice President of Chemical and Screening Sciences at Wyeth Research. “Medicinal chemistry is one of the key components of our drug discovery efforts and has resulted in many important drug candidates. We are very proud of our colleagues who have been honored and are excited for their continued contribution to cutting-edge research and the subsequent contributions to global health care.”
The American Chemical Society, the world’s largest scientific society, is a nonprofit organization chartered by the U.S. Congress and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences.
Presented by the ACS Division of Medicinal Chemistry, the David W. Robertson Award for Excellence in Medicinal Chemistry was created in 2005 in memory of David W. Robertson, a medicinal chemist at Pfizer Global Research and Development.
About Wyeth Pharmaceuticals
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women’s health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.
Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and nonprescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
WYETH DISCLOSURE NOTICE: The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products, including with respect to our pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; data generated on our products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption “Item 1A, RISK FACTORS.” The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Wyeth
CONTACT: Media, Michael Lampe, +1-484-865-1346, or Doug Petkus,+1-973-660-5218, both of Wyeth; or Investors, Justin Victoria,+1-973-660-5340, for Wyeth
Web site: http://www.wyeth.com/
